• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioCision forms MedCision

BioCision forms MedCision

December 1, 2016
CenterWatch Staff

BioCision, a life science research and development company that standardizes basic laboratory processes, has announced the formation of MedCision, an independent company focused on automation of preclinical and clinical processes.

“The formation of MedCision is driven by a critical need in the market—innovative, standardization technologies and solutions for translational, clinical and point-of-care settings,” said Rolf O. Ehrhardt, M.D., Ph.D., BioCision CEO. “MedCision will be a leader in developing and commercializing innovative instruments for crucial processes in the post-manufacturing cell and gene therapy space.”

Dr. Ehrhardt continued, “The name of the company, MedCision, creates a clear connection to our BioCision roots but also conveys an evolution from those roots as our technology will focus on automating point-of-care clinical processes.”

The creation of MedCision as a stand-alone company with a dedicated management team will provide the necessary focus and foundation for long-term value generation in the clinical tools space. Commercialization of the award-winning ThawSTAR cell thawing platform will initially be the focus of MedCision.

Cell thawing, the last step a cellular product undergoes before patient administration, is one of the most important parts of the post manufacturing process. Rapid, uniform, non-fluid based thawing is necessary to maintaining therapeutic efficacy. ThawSTAR’s automated cell thawing platform makes it easy to ensure proper clinical handling and thawing across a range of volumes and storage formats. At the same time, the platform automatically incorporates temperature monitoring and data connectivity, both of which are critical to ensuring proper sample tracking and patient safety.

The ThawSTAR platform is experiencing rapid adoption into cell therapy research and development as part of clinical trials and will accelerate with the soon-to-be-announced Early Adopter Program. As the flagship product of this new company, the ThawSTAR platform will be expanded over the next 12 months with additional models and features.

MedCision corporate offices will be headquartered in San Rafael, California and spearheaded by former members of the BioCision senior management team. Rolf Ehrhardt, will serve as president and CEO, Ron DiNocco, chief financial officer and VP of Corporate Development, Eric Kunkel, SVP of Research and Development and Sam Kent, SVP Global Sales and Business Development.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing